RxDoctor Payments Data

Denis Patterson, DO

Pain Medicine · Reno, NVNPI 1538149950

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by AbbVie at 27.4% of the total. Among pain medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$815,658in general payments, 2019–2025

Across 1,705 payments — averaging $478.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$223K
  • Abbott$192K
  • Vertos Medical, Inc.$173K
  • Stryker$62K
  • Foundation Fusion Solutions, LLC$41K
  • Amgen$29K
  • plus $96K from 47 others
$473,742in research payments, 2019–2025

Across 583 payments — averaging $812.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$378K
  • Saluda Medical Americas, Inc.$42K
  • Biotronik Inc.$29K
  • Si-bone, Inc.$20K
  • Vertiflex, Inc.$3K
  • Nevro Corp.$2K
  • plus $375 from 1 others

What the payments were for

  • Consulting fees$375,68546%
  • Speaking & faculty fees$300,06137%
  • Travel & lodging$82,19610%
  • Food & beverage$50,5916%
  • Education$7,0701%
  • Entertainment$560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$815,658 in reported general payments places this provider in the 95th percentile of 101 pain medicine providers in Nevada.

See all pain medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$421,715
Medicare patients
558
Services billed
4,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina52$83,616
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen58$597
Oxycodone Hcl27$287
Gabapentin16$253
Pregabalin11$220
Cephalexin35$200
Diazepam115$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$223,354$83,61652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 pain medicine providers in Nevada.

Other pain medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →